catalog number :
MBS690083
products full name :
Mouse Anti-Human Kallikrein 7
products short name :
Kallikrein 7
products name syn :
KLK7; hK7; SCCE; PRSS6
other names :
kallikrein-7 isoform 2; Kallikrein-7; kallikrein-7; signal protein; serine protease 6; stratum corneum chymotryptic enzyme; kallikrein 7 (chymotryptic, stratum corneum); kallikrein-related peptidase 7; Serine protease 6; Stratum corneum chymotryptic enzyme
other gene names :
KLK7; KLK7; hK7; SCCE; PRSS6; PRSS6; SCCE; hK7; hSCCE
uniprot entry name :
KLK7_HUMAN
specificity :
This antibody was selected for its ability to detect human Kallikrenin-7.
purity :
Protein G chromatography
form :
Lyophilized from a 0.2um filtered solution in phosphate-buffered saline (PBS).
storage stability :
Lyophilized samples are stable for 2 years from date of receipt when stored at -70 degree C. Reconstituted antibody can be aliquoted and stored frozen at < -20 degree C for at least for six months without detectable loss of activity.
tested application :
Western Blot (WB), Neutralization of Kalikrein-7: Yes
app notes :
WB: Yes (1:500-1:1000). Optimal dilutions should be determined by wach laboratory for each application.
other info1 :
Antibody Generation: This antibody was produced from a hybridoma (mouse myeloma fused with spleen cells from a mouse) immunized with human recombinant protein of Kallikrein-7. Antigen: Recombinant human Kallikrein-7
other info2 :
Buffer: PBS. Reconstitution: Reconstitute the antibody with 200 ul sterile PBS and the final concentration is 500 ug/ml.
products description :
The human tissue kallikrein (KLK) gene family contains 15 members that play important roles in cancer. Notably, kallikrein-1, also known as tissue kallikrein, cleaves kininogen to release the vasoactive kinin peptide, bradykinin or lysyl-bradykinin. Kallikrein-3, called prostate specific antigen (PSA), is an established tumor marker that aids in the diagnosis, staging, and follow up of prostate cancer. Kallikrein-4 is specifically expressed in the prostate and over-expressed in prostate cancer. Kallikrein-5 is widely expressed but found at high levels in skin, breast, brain and testis; over-expression is an indicator of poor prognosis in ovarian cancer. Kallikrein-8 is expressed in the brain and is a novel marker of ovarian and cervical cancer.
ncbi acc num :
NP_001193982.1
ncbi gb acc num :
NM_001207053.1
ncbi mol weight :
27,525 Da
ncbi pathways :
Degradation Of The Extracellular Matrix Pathway (576263); Extracellular Matrix Organization Pathway (576262)
ncbi summary :
This gene encodes a member of the kallikrein subfamily of serine proteases. These enzymes have diverse physiological functions and many kallikrein genes are biomarkers for cancer. The encoded protein has chymotrypsin-like activity and plays a role in the proteolysis of intercellular cohesive structures that precedes desquamation, the shedding of the outermost layer of the epidermis. The encoded protein may play a role in cancer invasion and metastasis, and increased expression of this gene is associated with unfavorable prognosis and progression of several types of cancer. Polymorphisms in this gene may play a role in the development of atopic dermatitis. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene, which is one of fifteen kallikrein subfamily members located in a gene cluster on chromosome 19. [provided by RefSeq, May 2011]
uniprot summary :
Function: May catalyze the degradation of intercellular cohesive structures in the cornified layer of the skin in the continuous shedding of cells from the skin surface. Specific for amino acid residues with aromatic side chains in the P1 position. Cleaves insulin A chain at '14-Tyr- -Gln-15' and insulin B chain at '6-Leu- -Cys-7', '16-Tyr- -Leu-17', '25-Phe- -Tyr-26' and '26-Tyr- -Thr-27'. Could play a role in the activation of precursors to inflammatory cytokines. Ref.11. Catalytic activity: Cleavage of proteins with aromatic side chains in the P1 position. Enzyme regulation: Inhibited by Zn2+ and Cu2+ at low micromolar concentrations. Inhibited by SERPINA12. Ref.11. Subcellular location: Secreted. Note: In ovarian carcinoma, secreted and also observed at the apical membrane and in cytoplasm at the invasive front. Ref.5. Tissue specificity: Abundantly expressed in the skin and is expressed by keratinocytes in the epidermis. Also expressed in the brain, mammary gland, cerebellum, spinal cord and kidney. Lower levels in salivary glands, uterus, thymus, thyroid, placenta, trachea and testis. Up-regulated in ovarian carcinoma, especially late-stage serous carcinoma, compared with normal ovaries and benign adenomas (at protein level). Ref.2 Ref.5. Induction: By estrogens and glucocorticoids in a breast carcinoma cell line. Ref.2 Ref.11. Sequence similarities: Belongs to the peptidase S1 family. Kallikrein subfamily.Contains 1 peptidase S1 domain.